APP and Alzheimer disease: Although the two previously known interaction sites in the APP N-terminal part of the TM domain and adjacent amyloidogenic JM region remain viable targets for AD drug development, the information about the novel binding site for sterol molecules, occupancy of which would modulate APP processing by secretases, suggests a possible strategy for development of sterol-based AD therapeutic agents targeting the novel site to avoid the pathological processing of APP.